Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains

HIV Medicine

Volumn 3, Issue 3, 2002, Pages 200-206

  Puchhammer Stockl E ^a   Steininger, C ^a   Geringer, E ^a   Heinz, F X ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antiviral therapy; HIV SEQ program; Resistance interpretation; Virtual phenotype

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CODON; CONTROLLED STUDY; DRUG EFFICACY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS STRAIN;

ANTI-HIV AGENTS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HUMANS; PHENOTYPE; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; SOFTWARE; VIRAL LOAD;

EID: 0036054193     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2002.00116.x     Document Type: Article

References (21)

1. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
2. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy
3. Zidovudine resistance and HIV-I disease progression during antiretroviral therapy
4. Antiretroviral drug resistance testing in adult HIV-I infection: Recommendations of an International AIDS Society-USA Panel
5. Clinical and laboratory guidelines fortheuse of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting
6. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
7. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
8. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
9. Mutations in retroviral genes associated with drug resistance
10. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries
11. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance
12. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: An expanded data model integrating natural language text and sequence analysis programs
13. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database
14. Performance of the applied Biosystems ViroSeq Human Immunodeficiency virus type 1 (HIV-1) Genotyping system fro sequence-based analysis of HIV-1 in pediatric plasma samples
15. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs
16. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
17. Phenotypic and genotypic resistance assays: Methodology, reliability and interpretations
18. CCTG 575: A randomized, prospective study of phenotype testing (Pheno) versus standard of care (SOC) for patients failing antiretroviral therapy (ARV)
19. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine
20. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
21. The development of resistance of HIV-1 to zalcitabine